Genmab
Aktiesnakken
TESLA
Genmab
NOVO
Bavarian Nordic
Zealand Pharma
Ennogie
Medico
Vestas
Chemometec
Grønne Aktier
Hansa Biopharma
Pharma
AMBU
Shipping
BITCOIN
Forsvarsaktier
GN Store Nord
Gubra
Politiksnakken
Amerikanske aktier
Banker og Finans
Biotek-snakken
Embla Medical
Laks
OLIE OG GAS
|
14/5 20:14 af E L |
second day of over 2 mio ADS in the US
|
|
14/5 20:05 af Solsen |
Just like waiting for christmas. Not many days before we se the partner.
|
|
|
14/5 18:32 af E L |
some notable Asco presentations; includes epco (link)
|
|
|
14/5 18:21 af E L |
;-)
|
|
14/5 17:49 af nohope |
I may not be right about everything, but in this case I´m sure I´m right
|
|
|
14/5 17:42 af Solsen |
Until now nohope are right - we all die.
|
|
14/5 17:31 af Bulder |
It's almost like a cure. You can live for so many years with MM, that you'll die from age anyway.
|
|
|
14/5 17:30 af Solsen |
EPCORITAMAB has show its value today !
|
|
|
14/5 17:29 af Solsen |
You are so right !
|
|
|
14/5 17:28 af Bulder |
Nevertheless it is very positive,that in the late lines, when all other options are used, there still is a possibility to have a sCR.
|
|
|
14/5 17:28 af Solsen |
And thats where the big money are.
|
|
|
14/5 17:27 af Solsen |
Perhaps not many but to many to first, second and perhaps third line.
|
|
|
14/5 17:25 af Solsen |
With Car-T you manipulate with the immune system in a way that you dont have 100% control. Some pts just suddenly die.
|
|
|
14/5 17:24 af E L |
yea, think so too. Jan said that from the beginning, didn't he. The market clearly overshot in car-t optimism when it first came out, where in this chat most have been relatively negative
|
|
|
14/5 17:23 af Solsen |
I still think its for the last choise - due to sideeffects (possible grade 5) and price.
|
|
|
14/5 17:20 af Solsen |
yes
|
|
|
14/5 17:19 af E L |
you mean the JNJ car-t?
|
|
|
14/5 17:18 af Solsen |
At the moment its no competitor to dara. I think we now can say no thread to dara the next 5 years either from Takeda or JNJ.
|
|
|
14/5 17:18 af E L |
"CD38-knockout NK cells, which have been designed in attempt to prevent fratricide and enhance the activity of daratumumab" (link)
|
|
|
14/5 17:15 af E L |
yes, it is getting a bit more press than the bcma/cd3. but i am glad JNJ feels comfortable showing it out now, had been so quiet about it
|
|
|
14/5 17:13 af Bulder |
Heavily pretreated pts
|
|
|
14/5 17:11 af Bulder |
Janssens bcma car-t har 100% ORR, 86% sCR men eet dødsfald pga CRS. (link)
|
|
|
14/5 16:00 af E L |
A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) (link)
|
|
|
14/5 16:00 af E L |
hang on, one more by Mrs Mateos even:
|
|
| ||
|
|
14/5 15:59 af GeorgeBest |
tak Pensionisten - 15:14
|
|
|
14/5 15:48 af E L |
DUOHEXABODY®-CD37 SHOWS POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL B-CELL LYMPHOMA MODELS IN VITRO AND IN VIVO (link)
|
|
|
14/5 15:48 af E L |
lol. let's put the DuoHexa up also:
|
|
14/5 15:48 af Helge Larsen/PI-redaktør |
Tak for links E L.
|
|
|
14/5 15:47 af Helge Larsen/PI-redaktør |
:-D
|
|
|
14/5 15:47 af E L |
ok Genmab just send the mail with EHA stuff that is easier...
|
|
|
14/5 15:42 af E L |
EVALUATION OF PHARMACODYNAMIC BIOMARKERS OF EPCORITAMAB (GEN3013; CD3XCD20): RESULTS FROM A PHASE 1/2 DOSE-ESCALATION STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (link)
|
|
|
14/5 15:42 af E L |
SUBCUTANEOUS EPCORITAMAB (GEN3013; CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: DOSE-ESCALATION DATA FROM A PHASE 1/2 TRIAL (link)
|
|
|
14/5 15:30 af E L |
SUPERIOR ANTI-TUMOR ACTIVITY OF HEXABODY®-CD38 IN PRECLINICAL MODELS OF MULTIPLE MYELOMA, B CELL LYMPHOMA AND ACUTE MYELOID LEUKEMIA (link)
|
|
|
14/5 15:04 af E L |
EHA abstracts available via (link)
|
|
|
14/5 14:34 af Solsen |
Var lidt hurtig. Bulder har svaret....
|
|
|
14/5 14:31 af Solsen |
Insidere udnyttede ikke warrants. Det ville være meddelt.
|
|
|
14/5 14:25 af GeorgeBest |
på hjemmesiden, investors, Corporate Governance, findes compensation report, hvor detaljer findes får dem der har lyst...
|
|
|
14/5 14:22 af GeorgeBest |
bestyrelse får ikke warrants, de får restricted stocks
|
|
|
14/5 14:16 af Bulder |
De 69090, der blev udmeldt forleden er til employees.
|
|
|
14/5 14:11 af GeorgeBest |
nej
|
|
|
14/5 14:10 af Sukkeralf |
Vi ved vel ikke noget om hvor stor en del der er tilfaldet nogen som kunne kaldes insidere
|
|
|
14/5 14:09 af Bulder |
I så fald er det ikke DDB, der har stået for det, som de plejer.
|
|
|
14/5 13:56 af Helge Larsen/PI-redaktør |
I går tydede dagens udvikling i høj grad på udsalg af warrants.
|
|
|
14/5 13:53 af Bulder |
Vi plejer at se en større intern DDB handel efter luk ved salg af realiserede warrants. Denne gang var der kun en handel med 500 styks. Kunne tyde på, at heller ikke de menige har solgt deres. Sikkert fornuftigt.
|
|
14/5 12:54 af Darvin |
:-) Må ikke/ vil ikke hvem vil sælge hvis man ved en aftale er på vej.
|
|
|
14/5 12:50 af lahn1 |
Spændende betragtning, som bekræfter Jan's varslede aftale :-)
|
|
|
14/5 12:48 af Helge Larsen/PI-redaktør |
Netop.
|
|
14/5 12:30 af JørgenVarnæs |
Jo. Man vil blive betegnet som insider og dermed låst
|
|
|
14/5 12:27 af Helge Larsen/PI-redaktør |
Hvis man ligger i kurspåvirkende forhandlinger må de vel ikke sælge?
|
|
|
14/5 12:22 af GeorgeBest |
Så er det fordi ingen i management har solgt. Menige ansatte skal ikke rapportere.
|